Todos Medical - Full Color Logo
  • R&D Pipeline
    • Proprietary Diagnostics
      • Videssa® Breast: Cancer Blood Test
      • LymPro™: Alzheimer's Blood Test
      • TolloTest™: Coronavirus 3CL Protease Test
      • TBIA: AI Cancer Platform
    • Antiviral Drug Development
      • Tollovir™: 3CL Protease Inhibitor
  • Products & Services
    • Lab Solutions
      • Provista Diagnostics: CLIA/CAP Lab
      • COVID Testing: Lab Supplies & Automated Solutions
    • Dietary Supplement
      • Tollovid™: 3CL Protease Inhibitor
  • Insights
    • Publications
    • News & Media
    • Downloads
    • How It Works: 3CL Protease Inhibitors
    • Case Study: Lab Automation
  • Investors
  • About
    • Management Team
    • Board of Directors
    • Advisors
    • Career Opportunities
    Add a button link here
    Contact Us

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Governance Documents
    • News & Events

    • Press Releases
    • IR Calendar
    • Email Alerts
    Sep 30, 2021 9:08am EDT

    Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®

    Sep 28, 2021 9:09am EDT

    Todos Medical Announces October Conference Calendar

    Sep 27, 2021 7:30am EDT

    Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™

    Sep 24, 2021 9:36am EDT

    Todos Medical Reports Second Quarter 2021 Financial Results

    Sep 24, 2021 9:01am EDT

    UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders

    Sep 23, 2021 8:37am EDT

    Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com

    Sep 20, 2021 8:30am EDT

    Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™

    Sep 17, 2021 9:27am EDT

    Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce

    Sep 15, 2021 1:36pm EDT

    Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders

    Sep 13, 2021 6:55am EDT

    Todos Medical to Present at H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)

    • arrow_back
    • 1…
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • …25
    • arrow_forward
    rss_feed News RSS
    • Email Alerts
    • Company Profile
    • Contacts
    • RSS News Feed

    Todos Medical - Full Color-1

     

    About Us

    Todos Medical Ltd. is an in vitro diagnostics company focused on the development of novel blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s Disease, and the distribution of comprehensive solutions for COVID-19 screening.

    OTCQB: TOMDF

    Contact Us

    Todos Medical Ltd.
    121 Derech Menachem Begin

    30th Floor
    Tel Aviv, Israel 6701203
    Phone: +972-73-207-7259

    Todos Medical U.S.A.
    40 Wall Street, Suite 2702

    New York, NY 10005
    Phone: +1-917-983-4229

    Sign Up

    Follow us on Twitter Follow us on Facebook Follow us on LinkedIn
    © 2023 Todos Medical. All rights reserved.